As of February 19, 2026 a clinical trial record for a natural history study of Angelman Syndrome has been updated to Not yet recruiting. The study is listed on ClinicalTrials.gov with identifier NCT07417137 and is sponsored by Massachusetts General Hospital in collaboration with Astellas Pharma Global Development, Inc. This status and sponsor pairing highlight ongoing planning to collect observational data in this neurodevelopmental condition and to inform potential future development steps, while maintaining a clear separation from any interventional device actions at this stage. The entry provides a checkpoint for researchers and regulatory teams to track initiation timelines and sponsor collaboration structures as this observational effort moves toward protocol finalization.
What changed?
The clinical trial entry for a natural history study of Angelman Syndrome confirms Not yet recruiting as the current status. The record carries the title A Natural History Study of Angelman Syndrome and lists two sponsors, Massachusetts General Hospital and Astellas Pharma Global Development, Inc. The public identifier NCT07417137 links to the official ClinicalTrials.gov page where details about the study design, enrollment plans, and status are published. This combination of factors reflects early planning in an observational framework and sets expectations for how data collection could shape future regulatory discussions without describing any device or therapy at this stage.
What is the study scope?
The study is described as a natural history study of Angelman Syndrome. This framing implies data collection to document disease trajectory and variability in the target population. The source text identifies the condition as Angelman Syndrome and lists the two sponsors but does not describe a device or an intervention. The absence of device related claims aligns with a non interventional approach typical for natural history records. Readers can anticipate forthcoming protocol details that will specify endpoints, data elements, and governance processes that underpin any future regulatory discussions or product development routes while remaining within observational research boundaries.
Who sponsors and what is the status?
The trial is sponsored by Massachusetts General Hospital and Astellas Pharma Global Development, Inc. The status Not yet recruiting indicates no active enrollment is underway at this time. The collaboration of a major academic center with a global pharmaceutical sponsor is common for observational studies designed to gather baseline data to inform future research decisions. The ClinicalTrials.gov entry provides official information on trial design, eligibility, contact details, and expected milestones and will be updated as planning evolves.
What are the regulatory implications?
From a regulatory perspective the entry describes an observational natural history design rather than a device intervention. Regulatory teams may focus on compliance with Good Clinical Practice and data protection requirements, informed consent for data use, and oversight by an Institutional Review Board or ethics committee. Although the source text does not present device specific claims or a regulatory submission plan, this type of study often serves to establish a data foundation that could inform future submissions for therapies or device based components in Angelman Syndrome while maintaining alignment with applicable regulatory standards.
What should readers do?
Regulatory and clinical professionals should review the official ClinicalTrials.gov entry to verify current status, sponsor information, and study scope. The provided link is the authoritative source for protocol details, inclusion criteria, and contact information. If the organization is involved in Angelman syndrome research or device development, this entry offers insight into possible data collection frameworks and collaboration opportunities that may shape later regulatory filings or product development timelines.
FAQ
- 1. What is the purpose of this study The title indicates a natural history study focusing on Angelman Syndrome; no device is described in the source text.
- 2. Who are the sponsors Massachusetts General Hospital and Astellas Pharma Global Development, Inc.
- 3. What is the status Not yet recruiting.
- 4. Where can I find official information The ClinicalTrials.gov entry linked in the source text provides the primary source for protocol and status.
- 5. Will this study involve a device The source text does not describe any device or device related endpoints.
Conclusion
The update confirms ongoing planning for a natural history study of Angelman Syndrome with two sponsor organizations. The Not yet recruiting status indicates there are steps ahead before any enrollment opens, while the public trial record serves as a central reference point for stakeholders and regulatory watchers. For researchers and industry teams the entry signals potential for future engagement in observational data collection and possible alignment with later development activities. Monitoring the ClinicalTrials.gov page will remain important for timely updates on protocol publication, enrollment milestones, and any regulatory disclosures that follow.
Disclaimer: This article is intended for professionals and is not legal advice. Regulatory interpretations rely on current guidance and the actual protocol documentation.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07417137?term=medical+device